Trial · NCT07913334
Impact of Nurse-Led Pulmonary Rehabilitation on Dyspnea, Fatigue and Self-Efficacy in COPD Patients
NCT07913334, Not applicable, Not yet recruiting, University of Health Sciences Lahore
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Impact of Nurse-Led Pulmonary Rehabilitation on Dyspnea, Fatigue and Self-Efficacy in COPD Patients. Trials, record NCT07913334. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07913334
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Impact of Nurse-Led Pulmonary Rehabilitation on Dyspnea, Fatigue and Self-Efficacy in COPD Patients
- NCT number
- NCT07913334
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 74 participants, estimated
- Lead sponsor
- University of Health Sciences Lahore
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Pulmonary rehabilitation
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dyspnea | 12 weeks | Dyspnea is defined as the sensation of breathlessness, and in this study, it will be measured using the Modified Medical Research Council (mMRC) Dyspnea Scale, which classifies breathlessness severity from 0 (no breathlessness) to 4 (severe breathlessness) Higher score indicates greater dyspnoea and lower score indicates improvement in dyspnoea |
| Secondary | Fatigue | 12 weeks | The Fatigue Severity Scale (FSS), developed by Krupp and LaRocca (1989), is a 9-item scale designed to measure the severity of fatigue and its impact on daily functioning. Each item is rated on a 7-point Likert scale, with higher scores indicating greater fatigue severity. The Cronbach's alpha of 0.88 demonstrates the scale's excellent internal consistency. The total score ranges from 9 to 63, Based on the FSS scoring system, low fatigue is defined as a total score ranging from 9 to 36, while high fatigue is defined as a score ranging from 37 to 63. This classification will help in understanding the severity of fatigue in participants and the potential impact on their daily lives |
| Secondary | Self efficacy | 12 weeks | The COPD Self-Efficacy Scale (CSES), developed by Wigal et al. (1991), is a 34-item tool designed to assess a patient's confidence in managing their COPD symptoms across various situations. Using a 5-point Likert scale, patients rate their confidence from "Very confident" to "Not at all confident" in handling challenges related to physical exertion, emotional stress, environmental factors, and behavioral risks. Higher scores indicate greater self-efficacy. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 35897469 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07913334
GET https://conductscience.org/api/trials/v1/NCT07913334/registered